These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19482200)

  • 1. Aspirin in primary prevention: sex and baseline risk matter.
    Algra A; Greving JP
    Lancet; 2009 May; 373(9678):1821-2. PubMed ID: 19482200
    [No Abstract]   [Full Text] [Related]  

  • 2. Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.
    Ann Intern Med; 2006 Mar; 144(5):I29. PubMed ID: 16520469
    [No Abstract]   [Full Text] [Related]  

  • 3. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.
    Pignone M; Earnshaw S; Pletcher MJ; Tice JA
    Arch Intern Med; 2007 Feb; 167(3):290-5. PubMed ID: 17296886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention.
    Annemans L; Wittrup-Jensen K; Bueno H
    J Med Econ; 2010; 13(3):418-27. PubMed ID: 20632895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin for CV prevention -- for which patients?
    Jackson AN; Hume AL
    J Fam Pract; 2011 Sep; 60(9):518-23. PubMed ID: 21901177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
    Hira RS; Kennedy K; Nambi V; Jneid H; Alam M; Basra SS; Ho PM; Deswal A; Ballantyne CM; Petersen LA; Virani SS
    J Am Coll Cardiol; 2015 Jan; 65(2):111-21. PubMed ID: 25593051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Taking aspirin for prevention of "traveler's thrombosis"?].
    Stiefelhagen P
    Med Monatsschr Pharm; 2014 Jul; 37(7):259-60. PubMed ID: 25065162
    [No Abstract]   [Full Text] [Related]  

  • 11. Aspirin for primary prevention: yes or no?
    Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
    J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
    Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
    Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Aspirin Primary Prevention Conundrum.
    Schamroth Pravda M; Schamroth Pravda N; Beigel Y; Matetzky S; Beigel R
    Isr Med Assoc J; 2020 Jan; 22(1):60-63. PubMed ID: 31927808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart failure in sinus rhythm: no routine antithrombotic therapy.
    Prescrire Int; 2015 Jan; 24(156):25. PubMed ID: 25729838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders.
    Finazzi G
    Lupus; 2012 Jun; 21(7):747-50. PubMed ID: 22635221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
    Gianetti J; Gensini G; De Caterina R
    Thromb Haemost; 1998 Dec; 80(6):887-93. PubMed ID: 9869155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin in essential thrombocythemia: status quo and quo vadis.
    Griesshammer M; Bangerter M; van Vliet HH; Michiels JJ
    Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antiaggregation: aspirin].
    Eichenberger A; Pontiggia L; Beer JH
    Ther Umsch; 2003 Jan; 60(1):15-8. PubMed ID: 12638472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: Recommendations From the U.S. Preventive Services Task Force.
    Ann Intern Med; 2016 Jun; 164(12):. PubMed ID: 27064765
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.